Gene transfer into the central nervous system using Herpes Simplex Virus-1 vectors

• Autorzy: Tabbaa S , Goulah C. , Tran R.K. , Lis A. , Korody R. , Stachowski B. , Horowitz J.M. , Torres G. , Stachowiak E.K. , Bloom D.C. , Stachowiak M.K.
• Języki publikacji: EN

Abstrakty

EN

Manipulation of gene expression in developing or in mature central nervous systems (CNS) holds a promise for the resolution of many compelling neurobiological questions, including the feasibility of gene therapy to treat diseases of the brain. In this context, a number of viral vectors have been used in recent years to introduce and express genes into the CNS. This article discusses a gene transfer system based on the Herpes Simplex Virus-1 (HSV-1). We describe here the use of non-replicating, non-toxic HSV-1 vector, 8117/43, in a series of studies carried in our joint program. This vector proves further the utility of HSV-1 as a delivery vehicle to a number of distinct sites within the CNS.

Słowa kluczowe

EN

gene therapy; substantia nigra; gene transfer; herpes simplex virus type 1; hippocampus; central nervous system; beta-galactosidase

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2000
• Tom: 59
• Numer: 4
• Opis fizyczny: p.221-232,fig.

Twórcy

autor

Tabbaa S

• State University of New York, 317 Farber Hall, Buffalo N.Y. 14214, USA

autor

Goulah C.

autor

Tran R.K.

autor

Lis A.

autor

Korody R.

autor

Stachowski B.

autor

Horowitz J.M.

autor

Torres G.

autor

Stachowiak E.K.

autor

Bloom D.C.

autor

Stachowiak M.K.

Bibliografia

• 1. Andersen JK, Garber DA, Meaney CA, and Breakefield XO (1992) Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuronspecific enolase promoter. Hum Gene Ther, 3: 487–499.
• 2. Berthomme H, Lokensgard J, Yang L, Margolis T, and Feldman L T (2000) Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency. J Virol, 74: 3613–3622.
• 3. Bloom DC, Lokensgard JR, Maidment NT, Feldman LT, and Stevens JG (1994) Long-term expression of genes in vivo using non-replicating HSV vectors. Gene Ther, 1: S-36–38.
• 4. Bloom DC, Maidment NT, Tan A, Dissette VB, Feldman LT, and Stevens JG (1995) Long-term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus. Mol Brain Res, 31: 48–60.
• 5. Davar G, Kramer M F, Garber D, Roca AL, Andersen JK, Bebrin WDMC, Kosz-Vnenchak M, Knipe DM, and Breakefield XO (1994) Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J Comp Neurol, 339: 3–11.
• 6. Dobson AT, Margolis TP, Sedarati F, Stevens JG, and Feldman LT (1990) A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron, 5: 353–60.
• 7. During MJ, Naegele JR, O’Malley KL, and Geller AI (1994) Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science, 266: 1399–1403.
• 8. Federoff HJ, Geschwind MD, Geller AI, and Kessler JA (1992) Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA, 89: 1636–1640.
• 9. Fink DJ, Sternberg LR, Weber PC, Mata M, Goins WF, and Glorioso JC (1992) In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther, 3: 11–19.
• 10. Glorioso JC, Goins WF, and Fink DJ (1992) Herpes simplex virus-based vectors. Sem Virology, 3: 265–276.
• 11. Kuypers HGJM, and Ugolini G (1990) Viruses as transneuronal tracers. Trends Neurosci, 13: 71–75.
• 12. Lokensgard JR, Berthomme H, and Feldman LT (1997) The latency-associated promoter of herpes simplex virus type 1 requires a region downstream of the transcription start site for long-term expression during latency. J Virol, 71: 6714–6719.
• 13. Lokensgard JR, Bloom DC, Dobson AT, and Feldman LT (1994) Long-term promoter activity during herpes simplex virus latency. J Virol, 68: 7148–7158.
• 14. Margolis TP, Bloom DC, Dobson AT, Feldman LT, and Stevens JG (1993) LAT promoter activity decreases dramatically during the latent phase of ganglionic infection with HSV. Virology, 197: 85–592.
• 15. Palmer JA, Branston RH, Lilley CE, Robinson MJ, Groutsi F, Smith J, Latchman DS, and Coffin RS (2000) Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol, 74: 5664–5618.
• 16. Rock DL, and Fraser NW (1985) Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region. J Virol, 55: 849–852.
• 17. Sedarati F, Margolis TP, and Stevens JG (1993) Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome. Virology, 192: 687–691.
• 18. Stevens JG. (1989) Human herpes viruses: a consideration of the latent state. Microbiol Rev, 53: 318–332.
• 19. Stevens JG, Wagner EK, Devi RGB, Cook ML, and Feldman LT. (1987) RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons. Science, 235: 1056–1059.
• 20. Wagner EK, and Bloom DC (1997) Experimental investigation of herpes simplex virus latency. Clin Micro Reviews, 10: 419–443.
• 21. Wolfe JH, Deshmane SL, and Fraser NW (1992) Herpes virus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nature Gen, 1: 379–384.